CAMBRIDGE, Mass., April 29, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the last patient has been enrolled in the second cohort of a randomized, three-cohort Phase 2 clinical trial of MM-121 in combination with erlotinib for the treatment of non-small cell lung cancer (NSCLC) patients. Developed in collaboration with Sanofi, MM-121 is a fully human monoclonal antibody that targets ErbB3, a cell surface receptor implicated in tumor growth and survival.
Merrimack Pharmaceuticals Completes Enrollment Of Second Cohort In Phase 2 Study Of MM-121 In Non-Small Cell Lung Cancer
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts